Profile data is unavailable for this security.
About the company
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
- Revenue in USD (TTM)539.00k
- Net income in USD-72.33m
- Incorporated2017
- Employees61.00
- LocationCG Oncology Inc400 Spectrum Center Drive, Suite 2040IRVINE 92618United StatesUSA
- Phone+1 (949) 288-6298
- Fax+1 (302) 531-3150
- Websitehttps://www.cgoncology.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Maravai Lifesciences Holdings Inc | 274.10m | -131.04m | 2.17bn | 570.00 | -- | 5.28 | -- | 7.91 | -0.9917 | -0.9917 | 2.08 | 1.63 | 0.1458 | 2.93 | 5.90 | 421,690.80 | -8.49 | 12.67 | -11.29 | 15.46 | 44.03 | 74.79 | -58.27 | 37.32 | 10.47 | -2.02 | 0.4169 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
Iovance Biotherapeutics Inc | 1.90m | -449.64m | 2.18bn | 557.00 | -- | 3.20 | -- | 1,143.43 | -1.82 | -1.82 | 0.0077 | 2.43 | 0.0023 | -- | -- | 3,418.31 | -53.07 | -51.47 | -59.00 | -57.56 | -846.22 | -- | -23,615.70 | -137,873.80 | 4.42 | -- | 0.0015 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
Intellia Therapeutics Inc | 52.60m | -485.50m | 2.19bn | 526.00 | -- | 2.11 | -- | 41.69 | -5.37 | -5.37 | 0.5827 | 10.76 | 0.0393 | -- | 2.55 | 100,007.60 | -36.27 | -31.34 | -39.21 | -34.53 | -- | -- | -922.94 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
Deciphera Pharmaceuticals Inc | 174.91m | -190.42m | 2.21bn | 355.00 | -- | 6.65 | -- | 12.64 | -2.21 | -2.21 | 2.03 | 3.85 | 0.3607 | 0.2287 | 6.35 | 492,704.20 | -39.26 | -44.54 | -47.45 | -52.24 | 96.95 | -- | -108.87 | -245.88 | 3.94 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
Janux Therapeutics Inc | 7.29m | -55.59m | 2.29bn | 64.00 | -- | 3.49 | -- | 314.22 | -1.22 | -1.22 | 0.159 | 12.65 | 0.014 | -- | 11.48 | 113,859.40 | -10.67 | -- | -10.95 | -- | -- | -- | -762.92 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
Novocure Ltd | 525.66m | -192.74m | 2.31bn | 1.45k | -- | 6.44 | -- | 4.40 | -1.81 | -1.81 | 4.92 | 3.34 | 0.4579 | 3.57 | 7.51 | 361,774.90 | -16.79 | -7.74 | -19.40 | -8.95 | 74.82 | 77.22 | -36.67 | -14.69 | 5.99 | -- | 0.6132 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
Celldex Therapeutics, Inc. | 6.07m | -144.88m | 2.33bn | 160.00 | -- | 2.77 | -- | 382.96 | -2.84 | -2.84 | 0.1182 | 12.72 | 0.0102 | -- | 3.05 | 37,950.00 | -24.28 | -29.65 | -25.16 | -31.42 | -- | -- | -2,385.97 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
CG Oncology Inc | 539.00k | -72.33m | 2.33bn | 61.00 | -- | 4.09 | -- | 4,314.92 | -1.13 | -1.13 | 0.0084 | 8.54 | -- | -- | -- | 8,836.07 | -- | -- | -- | -- | -- | -- | -10,551.39 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
Fortrea Holdings Inc | 3.01bn | -100.60m | 2.37bn | 16.00k | -- | 1.49 | -- | 0.7882 | -1.13 | -1.37 | 33.82 | 17.81 | 0.7036 | -- | 3.10 | 167,050.00 | -2.35 | -- | -2.84 | -- | 16.64 | -- | -3.35 | -- | -- | 0.2534 | 0.5035 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
ADMA Biologics Inc | 283.18m | -3.64m | 2.43bn | 624.00 | -- | 15.79 | 508.94 | 8.57 | -0.0204 | -0.0204 | 1.23 | 0.6632 | 0.8188 | 0.9923 | 7.44 | 453,808.40 | -1.05 | -24.80 | -1.21 | -28.00 | 40.13 | 17.40 | -1.29 | -51.31 | 1.86 | 2.19 | 0.4598 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
Apogee Therapeutics Inc | 0.00 | -103.55m | 2.44bn | 91.00 | -- | 2.93 | -- | -- | -2.04 | -2.04 | 0.00 | 14.22 | 0.00 | -- | -- | 0.00 | -21.45 | -- | -22.20 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
Rhythm Pharmaceuticals Inc | 91.93m | -273.87m | 2.44bn | 226.00 | -- | 39.57 | -- | 26.51 | -4.62 | -4.62 | 1.57 | 1.01 | 0.3042 | 1.53 | 8.06 | 406,747.80 | -90.64 | -47.21 | -108.65 | -52.84 | 88.37 | -- | -297.93 | -681.38 | 4.20 | -139.42 | 0.6355 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
TG Therapeutics Inc | 289.33m | 41.20m | 2.45bn | 284.00 | 71.89 | 15.30 | 59.21 | 8.47 | 0.2205 | 0.2205 | 1.97 | 1.04 | 1.01 | 0.3567 | 7.86 | 1,095,962.00 | 14.44 | -62.87 | 20.20 | -80.06 | 93.53 | -- | 14.24 | -405.03 | 2.84 | 4.01 | 0.3876 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
ACADIA Pharmaceuticals Inc | 813.81m | -1.71m | 2.46bn | 610.00 | -- | 5.29 | 275.06 | 3.02 | -0.0129 | -0.0129 | 4.93 | 2.81 | 1.08 | 1.85 | 10.13 | 1,363,159.00 | -0.2264 | -27.50 | -0.3579 | -32.73 | 92.27 | 95.62 | -0.2101 | -38.35 | 1.86 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
Structure Therapeutics Inc (ADR) | 0.00 | -97.68m | 2.47bn | 111.00 | -- | 5.76 | -- | -- | -2.32 | -2.32 | 0.00 | 9.22 | 0.00 | -- | -- | 0.00 | -27.73 | -- | -29.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Ally Bridge Group (NY) LLCas of 25 Jan 2024 | 2.49m | 3.74% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.19m | 3.29% |
BVF Partners LPas of 31 Mar 2024 | 1.88m | 2.83% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.54m | 2.31% |
Janus Henderson Investors US LLCas of 31 Mar 2024 | 1.52m | 2.28% |
Avidity Partners Management LPas of 31 Mar 2024 | 1.45m | 2.18% |
RA Capital Management LPas of 31 Mar 2024 | 1.40m | 2.10% |
Perceptive Advisors LLCas of 31 Mar 2024 | 1.30m | 1.96% |
Braidwell LPas of 31 Mar 2024 | 1.13m | 1.70% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 975.12k | 1.46% |